The past decade has witnessed rapid progress in mass spectrometry (MS)-based quantitative proteomics with the development of software and data analysis tools to interrogate large amounts of MS data. Quantitative proteomic technologies have shown great potential in delineating dysregulated proteomes in diseases such as cancer (1-4). Quantitative schemes via either stable isotope labeling or label-free quantitation (LFQ) 1 are used widely to assist MS for quantitative assessments of the changes in protein expression, post-translational modifications (5), and protein-protein interactions (6) in many biological systems, including tumor samples (7-11). However, the integration of accuracy, sensitivity, and totality in the analysis of tumor-specific proteoforms from individual patients still remains challenging with the current quantitative platforms. For example, strategies to increase analytical throughput (12) for tumor analysis have utilized the multiplexing advantage of isobaric mass tags such From the ‡Department